Could nanoparticles improve survival in treatment-resistant leukemia?
Researchers from the University of Connecticut have been focusing on alternative therapies for cancer, which will enable clinicians to treat cancers that are first-line therapy resistant. Nanoparticles have been used increasingly as a means of delivering salvage therapies, such as in this research published in Nature Cell Biology on treatment-resistant leukemia. Leukemia gives rise to significant treatment challenges due to the nature of the cancer. The disease affects the newly forming blood stem cells in bone marrow. The first line treatment currently takes the form of chemotherapy to kill the cancerous white blood cells, which are most commonly affected. However,...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!